Biotinylated TSLPR Fc&Avi Tag Protein, Human

TSLPR, or thymic stromal lymphopoietin receptor, also known as cytokine receptor-like factor 2 (CRLF2), belongs to the type I cytokine receptor family and structurally comprises an extracellular domain (containing the WSXWS motif), a single transmembrane domain, and an intracellular domain (harboring Box1/Box2 motifs); it lacks intrinsic kinase activity and must form a heterodimeric complex with the interleukin-7 receptor alpha chain (IL-7Rα) to transduce signals. Functionally, TSLPR serves as the specific receptor subunit for TSLP, and upon TSLP binding, the complex activates multiple downstream signaling pathways, predominantly the JAK-STAT (primarily STAT5), PI3K-AKT, and MAPK cascades, thereby driving Th2-type immune responses, promoting B-cell development, and maintaining immune homeostasis under physiological conditions, whereas under pathological states it becomes a core pathogenic mediator in allergic diseases such as asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps; moreover, TSLPR overexpression (mostly resulting from CRLF2 gene translocations or mutations) has been established as a major driver of high-risk B-cell acute lymphoblastic leukemia (B-ALL), significantly increasing relapse risk by enhancing leukemic cell proliferation, survival, and chemoresistance. Clinically, therapeutic strategies targeting the TSLP/TSLPR signaling axis have achieved milestone breakthroughs—the anti-TSLP monoclonal antibody Tezepelumab has been approved for severe asthma, while the novel anti-TSLPR antibody ASP7266 has demonstrated therapeutic potential for allergic diseases in preclinical studies; concurrently, peripheral blood TSLP/TSLPR expression levels as non-invasive biomarkers for diseases such as chronic rhinosinusitis, together with TSLPR overexpression as a predictive indicator for high-risk stratification in B-ALL, are driving the translational application of this signaling axis from fundamental immunoregulation toward precision therapy for allergic diseases and prognostic evaluation in hematological malignancies.